Duality Biotherapeutics Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Millions CNY. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023
Period Ending	Jun '25 Jun 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023
Cash & Equivalents	2,994	1,209	1,131
Short-Term Investments	706.96	188.06	5.26
Cash & Short-Term Investments	3,701	1,397	1,136
Cash Growth	-	22.96%	-
Accounts Receivable	298.56	379.02	100.8
Other Receivables	18.59	70.44	32.55
Receivables	317.15	449.46	133.35
Restricted Cash	45.65	45.16	42.65
Other Current Assets	25.64	18.26	21.75
Total Current Assets	4,090	1,910	1,334
Property, Plant & Equipment	18.05	18.6	17.76
Other Intangible Assets	39.43	46.24	54.25
Other Long-Term Assets	29.97	115.56	94.01
Total Assets	4,177	2,090	1,500
Accounts Payable	666.78	670.91	234.81
Accrued Expenses	-	38.97	25.24
Current Portion of Leases	1.51	2.99	2.91
Current Income Taxes Payable	-	1.72	0.92
Current Unearned Revenue	74.52	90.26	156.13
Other Current Liabilities	59.11	3,067	2,141
Total Current Liabilities	865.3	3,872	2,561
Long-Term Leases	3.01	2.3	2.41
Long-Term Unearned Revenue	224.04	238.25	60.16
Total Liabilities	1,264	4,112	2,624
Common Stock	0.06	0.01	0.01
Retained Earnings	-4,313	-2,161	-1,111
Comprehensive Income & Other	7,226	133.26	-19.2
Total Common Equity	2,913	-2,028	-1,130
Shareholders' Equity	2,913	-2,022	-1,124
Total Liabilities & Equity	4,177	2,090	1,500
Total Debt	67.89	5.29	5.32
Net Cash (Debt)	3,633	1,392	1,131
Net Cash Growth	-	23.07%	-
Net Cash Per Share	146.20	173.96	141.35
Filing Date Shares Outstanding	41.7	8	8
Total Common Shares Outstanding	41.7	8	8
Working Capital	3,224	-1,962	-1,227
Book Value Per Share	69.84	-253.46	-141.22
Tangible Book Value	2,873	-2,074	-1,184
Tangible Book Value Per Share	68.90	-259.24	-148.00
Machinery	-	10.74	7.61
Construction In Progress	-	0.55	0.19
Leasehold Improvements	-	6.92	6.33

Source: S&P Global Market Intelligence. Standard template. Financial Sources.